{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:28:28Z","timestamp":1792528108401,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Development of Janus-kinase (JAK) inhibitors has revolutionized the therapeutic landscape for patients with myeloproliferative neoplasia (MPN). Following approval of the first JAK1\/2-inhibitor Ruxolitinib, symptoms of this inflammatory disease, characterized by splenomegaly, release of inflammatory cytokines and appearance of thrombosis, could be effectively reduced for the first time. However, JAK-inhibitor treatment is limited in several aspects: 1) duration of response: 3\u00a0years after initiation of therapy more than 50% of patients have discontinued JAK-inhibitor treatment due to lack of efficacy or resistance; 2) reduction of disease burden: while effective in reducing inflammation and constitutional symptoms, JAK-inhibitors fail to reduce the malignant clone in the majority of patients and therefore lack long-term efficacy. Early clinical trials for patients with myelofibrosis (MF) have tried to address these issues for patients with suboptimal response to Ruxolitinib therapy while combination therapies with Fedratinib are rare. Recent reports provided first evidence on how the JAK2-V617F mutated myeloid cells may influence T-cell responses. JAK2-V617F promoted the synthesis of PD-L1 in MPN cells leading to limited anti-neoplastic T-cell responses, metabolic changes in T-cells and eventually JAK2-V617F-driven immune-escape of MPN cells. These findings may facilitate the use of immunotherapeutic approaches for JAK-mutated clones. Immune checkpoints refer to a variety of inhibitory pathways that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. The FRACTION study is a single arm, open label Phase II trial investigating the combination of Fedratinib with the PD-1 inhibitor Nivolumab in patients with myelofibrosis and suboptimal or lack of response to JAK-inhibitor therapy. Over a 12\u00a0months period the trial assesses longer term outcomes, particularly the effects on clinical outcomes, such as induction of clinical remissions, quality of life and improvement of anemia. No prospective clinical trial data exist for combinations of JAK- and immune-checkpoint-inhibitors in the planned MF study population and this study will provide new findings that may contribute to advancing the treatment landscape for MF patients with suboptimal responses and limited alternatives.<\/jats:p>","DOI":"10.1007\/s00277-024-05867-w","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T08:02:22Z","timestamp":1720166542000},"page":"2775-2785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)"],"prefix":"10.1007","volume":"103","author":[{"given":"Susanne","family":"Isfort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa Kathrin","family":"Al-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Moskwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Wohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"Manz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"5867_CR1","doi-asserted-by":"publisher","unstructured":"Perner F, Perner C, Ernst T, Heidel FH (2019) Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells 8(8):E854.\u00a0https:\/\/doi.org\/10.3390\/cells8080854","DOI":"10.3390\/cells8080854"},{"key":"5867_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.leukres.2018.10.001","volume":"74","author":"F Palandri","year":"2018","unstructured":"Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, Bergamaschi M, Tieghi A, Iurlo A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Ibatici A, Crugnola M, Heidel F, Bosi C, Bartoletti D, Auteri G, Catani L, Cuneo A, Aversa F, Semenzato G, Cavo M, Vianelli N, Benevolo G (2018) Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: results from a multicentre study on 284 patients. Leuk Res 74:86\u201388. https:\/\/doi.org\/10.1016\/j.leukres.2018.10.001","journal-title":"Leuk Res"},{"key":"5867_CR3","doi-asserted-by":"publisher","unstructured":"Palandri F, Palumbo GA, Bonifacio M, Elli EM, Tiribelli M, Auteri G, Trawinska MM, Polverelli N, Benevolo G, Tieghi A, Cavalca F, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Venturi M, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Branzanti F, Vianelli N, Cavo M, Heidel F, Iurlo A, Breccia M (2023) A prognostic model to predict ruxolitinib discontinuation and death in patients with myelofibrosis. Cancers (Basel). 15(20):5027. https:\/\/doi.org\/10.3390\/cancers15205027","DOI":"10.3390\/cancers15205027"},{"issue":"7836","key":"5867_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-020-2968-3","volume":"588","author":"AK Jayavelu","year":"2020","unstructured":"Jayavelu AK, Schnoder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schroder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hubner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M, Heidel FH (2020) Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature 588(7836):157\u2013163. https:\/\/doi.org\/10.1038\/s41586-020-2968-3","journal-title":"Nature"},{"issue":"3","key":"5867_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ajh.24976","volume":"93","author":"F Lussana","year":"2018","unstructured":"Lussana F, Cattaneo M, Rambaldi A, Squizzato A (2018) Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol 93(3):339\u2013347. https:\/\/doi.org\/10.1002\/ajh.24976","journal-title":"Am J Hematol"},{"issue":"5","key":"5867_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426\u2013435. https:\/\/doi.org\/10.1056\/NEJMoa1409002","journal-title":"N Engl J Med"},{"issue":"1","key":"5867_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjh.13519","volume":"171","author":"C Keohane","year":"2015","unstructured":"Keohane C, Kordasti S, Seidl T, Perez Abellan P, Thomas NS, Harrison CN, McLornan DP, Mufti GJ (2015) JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol 171(1):60\u201373. https:\/\/doi.org\/10.1111\/bjh.13519","journal-title":"Br J Haematol"},{"issue":"6","key":"5867_CR8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/bjh.13373","volume":"169","author":"S Parampalli Yajnanarayana","year":"2015","unstructured":"Parampalli Yajnanarayana S, Stubig T, Cornez I, Alchalby H, Schonberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P, Kroger N, Wolf D (2015) JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol 169(6):824\u2013833. https:\/\/doi.org\/10.1111\/bjh.13373","journal-title":"Br J Haematol"},{"issue":"2","key":"5867_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/leu.2013.296","volume":"28","author":"M Massa","year":"2014","unstructured":"Massa M, Rosti V, Campanelli R, Fois G, Barosi G (2014) Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia 28(2):449\u2013451. https:\/\/doi.org\/10.1038\/leu.2013.296","journal-title":"Leukemia"},{"issue":"9","key":"5867_CR10","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20(9):1043\u20131049. https:\/\/doi.org\/10.1038\/nm.3645","journal-title":"Nat Med"},{"issue":"12","key":"5867_CR11","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1136\/annrheumdis-2014-205615","volume":"73","author":"SP Wang","year":"2014","unstructured":"Wang SP, Iwata S, Nakayamada S, Sakata K, Yamaoka K, Tanaka Y (2014) Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis 73(12):2213\u20132215. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205615","journal-title":"Ann Rheum Dis"},{"key":"5867_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2016.10.005","volume":"77","author":"M Rizzi","year":"2017","unstructured":"Rizzi M, Lorenzetti R, Fischer K, Staniek J, Janowska I, Troilo A, Strohmeier V, Erlacher M, Kunze M, Bannert B, Kyburz D, Voll RE, Venhoff N, Thiel J (2017) Impact of tofacitinib treatment on human B-cells in vitro and in vivo. J Autoimmun 77:55\u201366. https:\/\/doi.org\/10.1016\/j.jaut.2016.10.005","journal-title":"J Autoimmun"},{"issue":"7","key":"5867_CR13","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122(7):1192\u20131202. https:\/\/doi.org\/10.1182\/blood-2013-03-484642","journal-title":"Blood"},{"issue":"4","key":"5867_CR14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/leu.2015.218","volume":"30","author":"F Perner","year":"2016","unstructured":"Perner F, Schnoder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, Frey S, Polanetzki A, Fahldieck C, Schonborn U, Schraven B, Isermann B, Fischer T, Heidel FH (2016) Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function. Leukemia 30(4):991\u2013995. https:\/\/doi.org\/10.1038\/leu.2015.218","journal-title":"Leukemia"},{"issue":"1","key":"5867_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H, C.-I. investigators, (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10(1):55. https:\/\/doi.org\/10.1186\/s13045-017-0417-z","journal-title":"J Hematol Oncol"},{"issue":"9","key":"5867_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"issue":"12","key":"5867_CR17","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","volume":"98","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM (2013) Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98(12):1865\u20131871. https:\/\/doi.org\/10.3324\/haematol.2013.092155","journal-title":"Haematologica"},{"issue":"7","key":"5867_CR18","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA (2017) Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 4(7):e317\u2013e324. https:\/\/doi.org\/10.1016\/S2352-3026(17)30088-1","journal-title":"Lancet Haematol"},{"issue":"6","key":"5867_CR19","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/leu.2015.87","volume":"29","author":"F Palandri","year":"2015","unstructured":"Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, Perricone M, Breccia M, Ottaviani E, Testoni N, Merli F, Aversa F, Alimena G, Cavo M, Martinelli G, Catani L, Baccarani M, Vianelli N (2015) Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia 29(6):1344\u20131349. https:\/\/doi.org\/10.1038\/leu.2015.87","journal-title":"Leukemia"},{"key":"5867_CR20","doi-asserted-by":"publisher","unstructured":"Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholoma M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kroger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R (2018) Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med 10(429). https:\/\/doi.org\/10.1126\/scitranslmed.aam7729","DOI":"10.1126\/scitranslmed.aam7729"},{"key":"5867_CR21","unstructured":"Medication Guide INREBIC\u00ae(fedratinib) (2019) [cited 2021 September]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212327s000lbl.pdf. Accessed\u00a008.02.2021"},{"key":"5867_CR22","unstructured":"Investigator's Brochure Nivolumab (2020) [cited 2021 September]; Available from: https:\/\/www.ctc.ucl.ac.uk\/TrialDocuments\/Uploaded\/BMS%20Nivolumab%20IB%20v19_tracked%20changes_17112020_0.pdf. Accessed\u00a019 Jun 2015"},{"key":"5867_CR23","volume-title":"Long-term safety of fedratinib in patients with intermediate- or high-risk myelofibrosis (MF), in 62nd ASH annual meeting","author":"RS Animesh Pardanani","year":"2020","unstructured":"Animesh Pardanani RS, Talpaz M, Cortes J, Gotlib J, Jamieson C, Rose S, Berry T, Zhang J, Tefferi A (2020) Long-term safety of fedratinib in patients with intermediate- or high-risk myelofibrosis (MF), in 62nd ASH annual meeting"},{"issue":"6","key":"5867_CR24","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ajh.25777","volume":"95","author":"CN Harrison","year":"2020","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Shen J, Berry T, Brownstein C, Mesa RA (2020) Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol 95(6):594\u2013603. https:\/\/doi.org\/10.1002\/ajh.25777","journal-title":"Am J Hematol"},{"issue":"10","key":"5867_CR25","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s00134-019-05704-z","volume":"45","author":"RS Hotchkiss","year":"2019","unstructured":"Hotchkiss RS, Colston E, Yende S, Crouser ED, Martin GS, Albertson T, Bartz RR, Brakenridge SC, Delano MJ, Park PK, Donnino MW, Tidswell M, Mayr FB, Angus DC, Coopersmith CM, Moldawer LL, Catlett IM, Girgis IG, Ye J, Grasela DM (2019) Immune checkpoint inhibition in sepsis: a phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med 45(10):1360\u20131371. https:\/\/doi.org\/10.1007\/s00134-019-05704-z","journal-title":"Intensive Care Med"},{"issue":"5","key":"5867_CR26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A (2015) Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 1(5):643\u2013651. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1590","journal-title":"JAMA Oncol"},{"issue":"6","key":"5867_CR27","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/SHK.0000000000001443","volume":"53","author":"E Watanabe","year":"2020","unstructured":"Watanabe E, Nishida O, Kakihana Y, Odani M, Okamura T, Harada T, Oda S (2020) Pharmacokinetics, pharmacodynamics, and safety of Nivolumab in patients with Sepsis-Induced Immunosuppression: a multicenter, open-label phase 1\/2 study. Shock 53(6):686\u2013694. https:\/\/doi.org\/10.1097\/SHK.0000000000001443","journal-title":"Shock"},{"issue":"5","key":"5867_CR28","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA Jr., Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H, IWGfM Research, and Treatment (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108(5):1497\u2013503. https:\/\/doi.org\/10.1182\/blood-2006-03-009746","journal-title":"Blood"},{"issue":"1","key":"5867_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.leukres.2010.07.015","volume":"35","author":"RP Gale","year":"2011","unstructured":"Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S (2011) What are RBC-transfusion-dependence and -independence? Leuk Res 35(1):8\u201311. https:\/\/doi.org\/10.1016\/j.leukres.2010.07.015","journal-title":"Leuk Res"},{"issue":"5","key":"5867_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.leukres.2012.01.023","volume":"36","author":"RP Gale","year":"2012","unstructured":"Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S (2012) RBC-transfusion guidelines update. Leuk Res 36(5):659\u2013660. https:\/\/doi.org\/10.1016\/j.leukres.2012.01.023","journal-title":"Leuk Res"},{"key":"5867_CR31","unstructured":"Pardanani A, Stone RM, Talpaz M, Cortes J, Gotlib J, Jamieson C, Rose SA, Berry T, Zhang J, Tefferi (2020) Long-term safety of fedratinib in patients with intermediate- or high-risk myelofibrosis (MF). Hemasphere (EHA Annual Meeting Abstracts 2020).\u00a0(Abstract release date: 05\/14\/20) EHA Library. 06\/12\/2020; 293585; EP1096"},{"issue":"6","key":"5867_CR32","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/sim.721","volume":"20","author":"RP A'Hern","year":"2001","unstructured":"A\u2019Hern RP (2001) Sample size tables for exact single-stage phase II designs. Stat Med 20(6):859\u2013866. https:\/\/doi.org\/10.1002\/sim.721","journal-title":"Stat Med"},{"issue":"4","key":"5867_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A (2018) MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol 36(4):310\u2013318. https:\/\/doi.org\/10.1200\/JCO.2017.76.4886","journal-title":"J Clin Oncol"},{"key":"5867_CR34","unstructured":"Griesshammer M, Baerlocher GM, D\u00f6hner K, Gisslinger H, Koschmieder S, Petrides PE, Lengfelder E (2018) Prim\u00e4re Myelofibrose (PMF). Onkopedia Leitlinien [cited 2021 August]; Available from: https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/primaere-myelofibrose-pmf\/@@guideline\/html\/index.html. Accessed\u00a031 Aug 2021"},{"issue":"10","key":"5867_CR35","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lubbert M, Wasch R, Scheid C, Stolzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Graff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kroger N, Passweg J, Halter J, Socie G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N (2015) Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10):2062\u20132068. https:\/\/doi.org\/10.1038\/leu.2015.212","journal-title":"Leukemia"},{"issue":"19","key":"5867_CR36","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socie G, Group RT (2020) Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med 382(19):1800\u20131810. https:\/\/doi.org\/10.1056\/NEJMoa1917635","journal-title":"N Engl J Med"},{"key":"#cr-split#-5867_CR37.1","unstructured":"Ahsan A, La Motte-Mohs R, Hagner P, Thakurta A (2021) Fedratinib demonstrates limited suppression of t- and Natural Killer- (NK) cell activity ex vivo compared with ruxolitinib at clinically relevant doses. Hemasphere (EHA annual meeting abstracts 2021).\u00a0EHA Library. Ahsan A. 06\/09\/21"},{"key":"#cr-split#-5867_CR37.2","unstructured":"Ahsan A, La Motte-Mohs R, Hagner P, Thakurta A (2021) Fedratinib demonstrates limited suppression of t- and Natural Killer-"},{"key":"#cr-split#-5867_CR37.3","unstructured":"(NK) cell activity ex vivo compared with ruxolitinib at clinically relevant doses. Hemasphere (EHA annual meeting abstracts 2021).\u00a0EHA Library. Ahsan A. 06\/09\/21; 324785; EP1062"},{"issue":"12","key":"5867_CR38","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1007\/s00277-021-04618-5","volume":"100","author":"I Abou Dalle","year":"2021","unstructured":"Abou Dalle I, Kantarjian H, Daver N, Masarova L, Pemmaraju N, Bose P, Garcia-Manero G, Verstovsek S (2021) Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol 100(12):2957\u20132960. https:\/\/doi.org\/10.1007\/s00277-021-04618-5","journal-title":"Ann Hematol"},{"issue":"23","key":"5867_CR39","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1182\/bloodadvances.2021005491","volume":"5","author":"G Hobbs","year":"2021","unstructured":"Hobbs G, Cimen Bozkus C, Moshier E, Dougherty M, Bar-Natan M, Sandy L, Johnson K, Foster JE, Som T, Macrae M, Marble H, Salama M, El Jamal SM, Zubizarreta N, Wadleigh M, Stone R, Bhardwaj N, Iancu-Rubin C, Mascarenhas J (2021) PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Adv 5(23):5086\u20135097. https:\/\/doi.org\/10.1182\/bloodadvances.2021005491","journal-title":"Blood Adv"},{"issue":"15","key":"5867_CR40","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1080\/14656566.2022.2135989","volume":"23","author":"JT England","year":"2022","unstructured":"England JT, Gupta V (2022) Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naive and exposed patients with myelofibrosis. Expert Opin Pharmacother 23(15):1677\u20131686. https:\/\/doi.org\/10.1080\/14656566.2022.2135989","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"5867_CR41","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05867-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05867-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05867-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:11:32Z","timestamp":1722060692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05867-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5867"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05867-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TG, LW and JR are employed by the IKF Frankfurt GmbH, which acts as the sponsor of this trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}